Carilizumab and chemo for advanced gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after one prior treatment.
- You have at least one measurable tumor that hasn't been treated with radiation recently.
- You are well enough to be up and about (ECOG score 0-1) and have adequate organ function.
- Your cancer is HER2 negative (a specific protein test).
- You have not had severe side effects from immunotherapy or prior treatment with paclitaxel drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
This trial tests a combination of two drugs: carilizumab (an immunotherapy) and apatinib (a targeted therapy) for patients with unresectable stage III or IV gastric cancer that has a specific DNA repair problem (dMMR). The goal is to see if this treatment can help shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a drug called camrelizumab, alone or with other treatments, for people with advanced stomach cancer that has worsened or returned. It aims to see how well this treatment works in real-world patients.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.